Esther A, Iftach S, Esther P
Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
FEBS Lett. 1994 Mar 14;341(1):99-103. doi: 10.1016/0014-5793(94)80248-3.
We have previously shown that topoisomerase I (topo I) antagonist inhibited retrovirus replication. Since tyrphostins, synthetic compounds and protein tyrosine kinases (PTKs) blockers, inhibited topo I activity (manuscript in preparation) we examined their ability to inhibit Moloney murine leukemia virus (Mo-MuLV) replication. We found that non-cytotoxic doses of tyrphostin derivatives (AG-555, AG-18) blocked or substantially reduced Mo-MuLV replication in acute or chronically infected NIH/3T3 cells. Our experiments suggest that the antiviral effect of these tyrphostin derivatives was not the result of antiproliferative activity. However, the tyrphostin derivatives used in our present investigation differ in their ability to inhibit Mo-MuLV replication. Furthermore, as expected from stereospecific competitive inhibitors, the antiviral effect is not a general characteristic of all tyrphostin derivatives, since AG-213 does not affect Mo-MuLV replication. Our results indicate that these tyrphostin derivatives may represent a novel class of antiretroviral drugs.
我们之前已经表明,拓扑异构酶I(topo I)拮抗剂可抑制逆转录病毒复制。由于酪氨酸磷酸化抑制剂(tyrphostins)这种合成化合物及蛋白酪氨酸激酶(PTKs)阻滞剂可抑制topo I活性(准备中的手稿),我们研究了它们抑制莫洛尼鼠白血病病毒(Mo-MuLV)复制的能力。我们发现,非细胞毒性剂量的酪氨酸磷酸化抑制剂衍生物(AG-555、AG-18)可阻断或显著降低急性或慢性感染的NIH/3T3细胞中Mo-MuLV的复制。我们的实验表明,这些酪氨酸磷酸化抑制剂衍生物的抗病毒作用并非抗增殖活性的结果。然而,我们目前研究中使用的酪氨酸磷酸化抑制剂衍生物在抑制Mo-MuLV复制的能力上存在差异。此外,正如立体特异性竞争性抑制剂所预期的那样,抗病毒作用并非所有酪氨酸磷酸化抑制剂衍生物的普遍特征,因为AG-213不影响Mo-MuLV复制。我们的结果表明,这些酪氨酸磷酸化抑制剂衍生物可能代表一类新型抗逆转录病毒药物。